About the Company

The stomach has been recently identified to be the site of origination of
some of the most common and bothersome GI symptoms, such as
heartburn, bloating, abdominal pain/discomfort and constipation. These
symptoms occur in clusters in functional disorders such as IBS (abdominal
pain/discomfort, gas, bloating, irregular bowel movements etc.), Dyspepsia
(heartburn/reflux, gastric pain, bloating, difficulty finishing a meal etc.) and
Constipation (fewer than three bowel movements per week, straining during
defecation, hard or lumpy stools, abdominal pain etc.).

Essential Oils (peppermint oil, caraway oil, etc.) are the purified active
ingredients in herbal plants and have demonstrated their effectiveness in
IBS (Irritable Bowel Syndrome) and FD (Functional Dyspepsia) in several
different RCTs (Randomized Placebo Controlled Clinical Trials).

However, delivery of the essential oils to the stomach has not been viable,
because these oils are lighter than the stomach fluid. This makes them float
on top of the stomach contents. The oils floating on top of the stomach fluid
can contact and open (with their smooth muscle relaxing activity) the
esophageal valve located near the top of the stomach and result in
undesirable symptoms.

Digest Pharma has developed a unique technology (patent pending) which
uses cellulosic fibers to convert the essential oils into dry essential oil containing pellets which sink rather than float in the stomach fluid. The size
of the pellets is controlled so that they can flow reliably through the valve
between the stomach and the intestines, even when the valve is closed. The
pellets slowly release/dissolve the oils as the pellets flow in the stomach and
the intestines.

Digest Pharma’s DEOP (Densified Essential Oil Pellets) technology allows safe
and effective delivery of essential oils to the stomach and intestines. All 3
products being commercialized by Digest Pharma’s use DEOP technology
(patent pending).

GutCalm® is Digest Pharma’s first commercial product (launched in March 2025), for IBS relief.

Digest Pharma’s second product Digest Calm™ was launched in early
October 2025. Digest Calm™ is for relief of Indigestion/Upset Stomach (Early
fullness, acid reflux, heartburn, bloating etc.)

The third product, LaxaCalm™ is being developed by Digest Pharma for constipation (planned launch 4Q, 2026).

Digest Pharma is a family-owned company based in Florida since 2023.
Syed M Shah, PhD is the founder and CEO of Digest Pharma. He invented and
developed IBgard® in 2012, when he co-founded Zx Pharma LLC in 2010.

He is the co-inventor on 80 US patents related to pharmaceuticals, medical foods, dietary supplements and foods.

Previously, Syed worked for 20+ years in pharmaceuticals research and
development for Pfizer, Wyeth and Lederle. He was awarded the 2020
Uber Elite award for his development of 4 blockbuster (more than $1.0 billion
yearly sales) pharmaceuticals

Available Now on Amazon

Available Now on Amazon